However, given the availability of several regimens with limited head-to-head comparisons from randomized controlled trials (RCTs), the identification of the optimal regimen of neoadjuvant with HER2-targeted therapy for HER2+ve breast cancers remains challenging. Here, ERBB2 is linked to breast cancer.